Physician profile
William Plum
NPI 1356731343
$3,210.82
in general payments reported to CMS, 2019-2025
13 companies · $2,256 in 2025
The $2,256 reported for 2025 was more than what 83% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.82 · 2022: $151 · 2023: $383 · 2024: $361 · 2025: $2,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614 · Honoraria: $1,250 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.38 |
| Honoraria | $1,250.00 |
| Education | $135.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $1,250.00 | 2025 | |
| Alcon Vision LLC | $670.77 | 2021-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Abbvie INC. | $449.02 | 2023-2025 | |
| Nova Eye, INC. | $212.42 | 2025 | |
| Glaukos Corporation | $191.47 | 2022-2025 | Idosetr |
| New World Medical,INC. | $129.89 | 2023-2025 | Streamline, Kahook Dual Blade, Clearpath |
| Mallinckrodt Hospital Products INC. | $99.99 | 2025 | Acthar |
| Bausch & Lomb Americas INC. | $57.08 | 2023-2024 | Miebo, Xiidra |
| Oyster Point Pharma, INC. | $42.62 | 2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $37.39 | 2024 | Dextenza |
| Harrow Eye, LLC | $25.35 | 2025 | |
| Apellis Pharmaceuticals, INC. | $22.68 | 2025 | Syfovre |
| Sight Sciences, INC. | $22.14 | 2024 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Plum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.